The BriLife jabs arrived in Georgia over the weekend to begin the trial, which will run simultaneously with trials in Israel.

The BriLife vaccine will be tested in Phase II and III trials in Georgia, Ukraine, and Israel as part of a deal with NRx Pharmaceuticals.

Scientists at the Israel Institute for Biological Research are looking into forgoing a second vaccine jab if a higher dose is given initially.